Welcome to our dedicated page for Mind Medicine news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine stock.
Mind Medicine Inc. (MNMD) is a clinical-stage biotech company pioneering research into psychedelic-inspired therapies for mental health disorders. This dedicated news hub provides investors and researchers with timely updates on MNMD's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases detailing clinical trial progress, partnership announcements with leading research institutions, and analyses of the company's novel approaches to treating conditions like addiction and depression. Our curated collection ensures you stay informed about MNMD's work developing therapies that target neuroplasticity through compounds such as LSD-analogs and psilocybin derivatives.
Key updates include Phase 2 trial results, intellectual property developments, executive leadership changes, and presentations at major medical conferences. All content is sourced from verified channels to maintain compliance with financial disclosure standards.
Bookmark this page for streamlined access to MNMD's evolving story in psychedelic medicine. Check regularly for critical updates about FDA-regulated research programs and breakthrough therapy designation tracking within this emerging biopharmaceutical sector.
Mind Medicine Inc. (NASDAQ: MNMD) reported its Q2 2022 financial results, highlighting the advancement of its Phase 2b dose-optimization trial for MM-120, targeting generalized anxiety disorder (GAD). The company announced positive safety results for MM-110, aimed at opioid withdrawal. As of June 30, 2022, cash and equivalents stood at $105.7 million, adequate to support operations into 2024. The net loss for Q2 2022 was $17.1 million, significantly reduced from $44.5 million in Q2 2021. Leadership changes were notable, including the appointment of Schond L. Greenway as CFO and two new independent board members.
On August 11, 2022, FCM MM Holdings, LLC, led by co-founder Dr. Scott Freeman, urged Mind Medicine (NASDAQ:MNMD) to adopt a new strategic plan. The proposals include a focus on core drugs MM-110 (18-MC) and MM-120 (LSD), reducing annual cash burn from $45 million to under $25 million, and halting the at-the-money equity offering. FCM believes these changes could expedite MM-120's market entry from eight years to four. With 5.6% of MindMed's shares, FCM is committed to enhancing shareholder value.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced a 1-for-15 reverse share split, aimed at meeting Nasdaq's minimum bid price requirement and facilitating future business needs. Post-split, approximately 28.4 million shares will be outstanding, with trading set to begin on August 29, 2022. Existing warrants and options will be adjusted correspondingly. Shareholders will not need to take action for holdings via brokers, while those with physical certificates will receive further instructions from Computershare. The company's focus remains on developing treatments for brain health disorders.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced it will host an earnings call on August 11, 2022, at 4:30 p.m. EDT to discuss its financial results for the quarter ended June 30, 2022, alongside a business update. The company focuses on developing innovative products targeting brain health disorders, including psychiatry and addiction. Stakeholders can join the call via telephone or watch the webcast, which will also be archived for 30 days.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced its participation in the Canaccord Genuity 42nd Annual Growth Conference, set for August 8-11, 2022, in Boston, MA. The management team will present on August 10 at 11:00 a.m. ET with an in-person format along with investor meetings. A live webcast will be accessible, and a replay will be available for 90 days on their website. MindMed is focused on developing innovative treatments for brain health disorders, targeting critical neurotransmitter systems.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced the results of its annual general and special meeting of shareholders held on June 1, 2022. All five management nominees were successfully elected as directors, with percentages of votes ranging from 89.04% to 96.72%. KPMG LLP was appointed as the company's auditor for the coming year. Additionally, shareholders approved an alteration to the company's share structure, eliminating Multiple Voting Shares and re-designating Subordinate Voting Shares as Common Shares. This strategic move aims to streamline the company's capital structure.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced its participation in the Jefferies Global Healthcare Conference in New York from June 8-10, 2022. CEO Robert Barrow will present on June 10, 2022, at 12:45 p.m. ET. The event includes an in-person presentation and one-on-one investor meetings. A webcast of the presentation will be available at this link, with a replay for 90 days on MindMed's website. MindMed focuses on developing treatments for brain health disorders.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced the appointment of Schond L. Greenway as Chief Financial Officer, effective May 23, 2022. Greenway brings over 20 years of experience in investment banking and corporate advisory, particularly in the life sciences sector. His expertise in US biotech capital markets is expected to advance MindMed's mission of developing innovative therapies for brain health disorders. With numerous near-term milestones ahead, the company aims to enhance its pipeline targeting conditions like anxiety, addiction, and autism.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced positive topline results from its Phase 1 trial of MM-110, a treatment for opioid withdrawal. Conducted on 108 healthy volunteers, the trial demonstrated that MM-110 was well-tolerated, with no serious adverse events reported. The findings support advancing to a Phase 2a trial, set to begin in Q2 2022. The study indicates MM-110's potential in addressing the opioid crisis, focusing on safety, tolerability, and neurocognitive effects. This progress builds on previous studies suggesting the drug's effectiveness in reducing withdrawal symptoms.
Mind Medicine (NASDAQ: MNMD) reported progress in its clinical programs for three lead drug candidates aimed at treating brain health disorders. The company appointed Dr. Francois Lilienthal as Chief Commercial Officer and confirmed a cash balance of $120.5 million as of March 31, 2022, adequate to cover operations into 2024. R&D expenses increased to $10.2 million, while general and administrative expenses rose to $8.3 million. MindMed anticipates multiple upcoming catalysts, including ongoing trials for MM-120, MM-402, and MM-110, which target anxiety, autism, and opioid use disorders respectively.
FAQ
What is the current stock price of Mind Medicine (MNMD)?
What is the market cap of Mind Medicine (MNMD)?
